12:00 AM
 | 
Dec 16, 2002
 |  BioCentury  |  Tools & Techniques

Paradigm's a priori knockouts

Knockout mouse company Paradigm Therapeutics plc says its ability to start with a gene and work towards medicinal chemistry differentiates it from other players in the space. Paradigm, which raised £12 million ($18.9 million) last week, was spun out from the University of Cambridge's Wellcome CRC Institute in the summer of 1999.

Focusing on known genes, Paradigm uses in silico methods to identify mouse orthologs to human genes of interest. Using mice, the company excises...

Read the full 352 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >